Genomics and Artificial Intelligence are two of the most promising technologies today. Individually, each provide unapparelled insight into millions of datapoints, and the combination of the two are leading to some of the greatest discoveries of our lifetime.In the U.S. alone, there are over 25 million people affected by rare genetic diseases andit is estimated that every year more than 400,000 children are born with one of these conditions. Genetic testing is quickly becoming the go-to procedure to effectively identify these conditions, allowing for improved patient outcomes and potential lives saved. Unfortunately, once a SNP Array test is prescribed and sequenced, Geneticists all over the world have traditionally spent millions of man-hours manually sifting through databases in order to identify and correlate a case to more than 7,000 rare diseases. That is, until now.Our SIVOTEC BioInformatics name derives from “Signatures in Vivo Through Technology” and our GENA™ AI platform provides commercial labs, hospitals and academic centers with the necessary tools to shorten their discovery cycle by over 95% (from days to just minutes) thus accelerating the time from testing-to-diagnosis and saving thousands of dollars per each sample sequenced thanks to improvements in workflow and the quality of results.

AI/ML

Biotechnology

Blockchain

GENA™

GENA™'s headquarters in Boca Raton, FL, United States

Pete Martinez

Richard Simon

Zhijhi Jiang

Christopher Mader

Nicholas Tsinoremas

Klaas Wierenga

GENA™

Org chart

Board & advisors

Teams

Offices

Similar companies